Danaher Corporation (NYSE:DHR) was discussed by Jim Cramer in relation to the performance of healthcare stocks. Despite recent gains, Cramer believes there is still significant upside potential for the stock. Danaher develops a range of medical, life sciences, and diagnostic products, but has not met expectations following its purchase in early 2022. While it remains a potential investment, some AI stocks may offer greater upside potential with less downside risk. Investors seeking undervalued AI stocks with growth potential may want to explore other options.

Read more at Yahoo Finance.: “It Has Been a Huge Disappointment”